LINKER-AL2NCT06292780
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 20 versions: 19 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 11 words
- Trial sites expanded: 21 → 24 locations
- Minor Study sites: 20 to 21v19
- Minor Study sites: 19 to 20v18
- Minor Study sites: 18 to 19v17
- Minor Study sites: 17 to 18v15
Show 13 earlier versionsHide 13 earlier versions
- Minor Study sites: 16 to 17v14
- Minor Study sites: 15 to 16v13
- Minor Study sites: 14 to 15v12
- Notable Eligibility criteria shortened, about 13 words
- Study sites: 7 to 14
- Minor Study sites: 6 to 7v10
- Minor Study sites: 5 to 6v9
- Minor Study sites: 4 to 5v8
- Minor Study sites: 2 to 4
- Start date changed from estimate of Aug 31, 2024 to Aug 7, 2024
- Minor Study sites: 1 to 2v6
- Notable Start date: Jun 30, 2024 to Aug 31, 2024v5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Notable Start date: May 31, 2024 to Jun 30, 2024v3
- Notable Start date: Apr 29, 2024 to May 31, 2024
- Primary completion date: Aug 26, 2028 to Aug 20, 2028
- Study completion date: Feb 26, 2035 to Feb 20, 2035
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of dose-limiting toxicity (DLTs)
Timeframe: Up to 28 Days
Achievement of hematologic complete response (CR) as determined by the Independent Review Committee (IRC)
Timeframe: Up to 3 years
Secondary (33)
Achievement of hematologic CR, as determined by the IRC
Achievement of hematologic very good partial response (VGPR) or better response (CR + VGPR), as determined by the IRC
Achievement of overall hematologic response (PR or better), as determined by the IRC
Time to initial hematologic response
Time to best hematologic response
Show 28 moreShow less
Duration of hematologic response (ie, best response, VGPR or better, overall response), as determined by the IRC
Hematologic progression-free survival (PFS)
Incidence of death
Incidence of treatment-emergent adverse events (TEAEs)
Severity of TEAEs
Incidence of serious adverse events (SAEs)
Severity of SAEs
Incidence of adverse events of special interest (AESIs)
Severity of AESIs
Achievement of overall hematologic response (PR or better), as determined by the IRC in dose regimen 1 vs 2
Incidence of TEAEs in dose regimen 1 vs 2
Severity of TEAEs in dose regimen 1 vs 2
Incidence of SAEs in dose regimen 1 vs 2
Severity of SAEs in dose regimen 1 vs 2
Incidence of AESIs in dose regimen 1 vs 2
Severity of AESIs in dose regimen 1 vs 2
Time from treatment initiation to hematologic disease progression as determined by the IRC
Time from treatment initiation to cardiac deterioration, as determined by the IRC
Time from treatment initiation to kidney deterioration as determined by the IRC
Time from treatment initiation to death as determined by the IRC
Time from initiation of treatment to date of death from any cause
Achievement of renal response in participants with renal involvement at baseline, as determined by IRC
Achievement of cardiac response in participants with cardiac involvement at baseline, as determined by IRC
Time to first renal response in participants with renal involvement at baseline
Time to first cardiac response in participants with cardiac involvement at baseline
Linvoseltamab concentration in serum over time
Incidence of anti-drug antibodies (ADAs) to linvoseltamab over time
Titers of ADAs to linvoseltamab over time
Arms and interventions
Phase 1: Cohort 1: Low DoseExperimental
Dose Escalation: Non-Randomized
Phase 1: Cohort 2: High DoseExperimental
Dose Escalation: Non-Randomized
Phase 2: Low DoseExperimental
Dose Expansion: Participants will be randomized in a 1:1 ratio
Phase 2: High DoseExperimental
Dose Expansion: Participants will be randomized in a 1:1 ratio
Drugs: Linvoseltamab
Sites
24 sites in 6 countries
United States 8, Spain 5, South Korea 4, Taiwan 3, United Kingdom 3, Greece 1